Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in Chinese subjects with advanced solid tumors
NCT02516527Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2015
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in solid tumor and melanoma, sponsored by Bristol Myers Squibb. Primary endpoints: Safety of ipilimumab, Tolerability of ipilimumab and 2 more. Started Oct 2015; status: completed.
02
Drugs
ipilimumab
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT02516527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516527.